These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29636998)

  • 1. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway.
    Chien YC; Liu LC; Ye HY; Wu JY; Yu YL
    Am J Cancer Res; 2018; 8(3):422-434. PubMed ID: 29636998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
    Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
    Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
    Huang JP; Ling K
    Oncol Lett; 2017 Nov; 14(5):5735-5742. PubMed ID: 29113202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.
    Shin YJ; Kim JH
    PLoS One; 2012; 7(1):e30393. PubMed ID: 22272343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes.
    Deb G; Shankar E; Thakur VS; Ponsky LE; Bodner DR; Fu P; Gupta S
    Mol Carcinog; 2019 Jul; 58(7):1194-1207. PubMed ID: 30854739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
    Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
    Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
    Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H
    Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.
    Verma A; Singh A; Singh MP; Nengroo MA; Saini KK; Satrusal SR; Khan MA; Chaturvedi P; Sinha A; Meena S; Singh AK; Datta D
    Nat Commun; 2022 Nov; 13(1):7344. PubMed ID: 36446780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer.
    Lawrence CL; Baldwin AS
    PLoS One; 2016; 11(10):e0165005. PubMed ID: 27764181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
    Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
    Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
    Mahara S; Lee PL; Feng M; Tergaonkar V; Chng WJ; Yu Q
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3735-44. PubMed ID: 27303043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.
    Lu H; Li G; Zhou C; Jin W; Qian X; Wang Z; Pan H; Jin H; Wang X
    Am J Cancer Res; 2016; 6(12):2737-2754. PubMed ID: 28042497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2.
    Dale B; Anderson C; Park KS; Kaniskan HÜ; Ma A; Shen Y; Zhang C; Xie L; Chen X; Yu X; Jin J
    ACS Pharmacol Transl Sci; 2022 Jul; 5(7):491-507. PubMed ID: 35837138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
    Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
    Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression.
    Gonzalez ME; Naimo GD; Anwar T; Paolì A; Tekula SR; Kim S; Medhora N; Leflein SA; Itkin J; Trievel R; Kidwell KM; Chen YC; Mauro L; Yoon E; Andò S; Kleer CG
    iScience; 2022 Aug; 25(8):104827. PubMed ID: 35992062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
    Chen Q; Zheng PS; Yang WT
    Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.
    Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY
    J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
    Cai L; Wang Z; Liu D
    Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.